Shannon John Patrick Jr's Form 4 filing
Xeris Biopharma Holdings, Inc. (XERS) · filed Aug 21, 2026
- Accession no.
- 0001867096-26-000073
- Filed
- Aug 21, 2026, 4:23 PM ET
- Trade date
- Aug 1, 2026
- Filing delay
- 20 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. It was filed 20 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shannon John Patrick JrCIK 0001553595 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2026 | Common Stock | FTax withholdingDisposed | −36,645 | $8.08 | −$296,091.6 | 2,898,933 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Chief Executive Officer and Chairman of the Board